The pharmaceutical industry has historically depended on relationships, conferences, intermediaries, and manual sourcing processes to identify licensing and supply opportunities. While those systems built longstanding business networks, they also created delays, limited visibility, and significant inefficiencies for companies trying to expand portfolios or enter new markets.
Mindaugas Zagorskis, co-founder and CEO of Pipelinepharma, believes the industry is now approaching a broader digital transformation.
“For years, pharmaceutical sourcing relied on fragmented information and offline networking,” Zagorskis says. “Companies often spend months identifying the right partner, validating product information, and starting conversations. That process is changing.”
Pipelinepharma was built around the idea that pharmaceutical pipeline intelligence and sourcing could operate more like a structured digital marketplace. The platform connects pharmaceutical buyers and sellers through a searchable database of CTD dossiers and finished dosage formulation opportunities.
According to the company, the platform now includes more than 90,000 dossiers from over 2,000 manufacturers worldwide. From Zagorskis’s perspective, one of the industry’s largest challenges has been the absence of centralized infrastructure capable of supporting efficient pipeline intelligence, sourcing, and dealmaking.
“There was no single environment where pharmaceutical companies could continuously discover products, evaluate opportunities, and engage with verified partners,” he says. “Most sourcing still depended on trade events, personal introductions, or disconnected databases.”
That fragmentation can create operational pressure for business development and licensing teams. Companies often need to evaluate regulatory documentation, manufacturing standards, market access considerations, and commercial fit across multiple regions simultaneously.
Pipelinepharma believes specialized data infrastructure is becoming increasingly important as pharmaceutical companies pursue faster licensing timelines and broader international expansion.
The company also argues that data quality matters as much as access itself. Zagorskis has publicly discussed concerns surrounding outdated sourcing information, incomplete records, and inaccurate data pulled from general internet searches or non-specialized tools.
“In pharmaceutical licensing, timing and accuracy are critical,” Zagorskis says. “Decisions cannot be based on assumptions or outdated information. Companies need verified and continuously updated intelligence.”
The shift toward digital sourcing also reflects wider changes across global B2B commerce. McKinsey research has shown that many corporate buyers now prefer digital engagement throughout complex purchasing journeys, including large transactions traditionally associated with in-person negotiations.
Zagorskis believes pharmaceutical dealmaking will continue moving in a similar direction, particularly as companies seek greater efficiency and portfolio flexibility.
At the same time, he does not believe digital infrastructure eliminates the importance of relationships. “Trust remains essential in pharmaceutical business development,” he says. “Technology should strengthen relationships by helping companies identify the right opportunities faster and focus their time on meaningful discussions rather than manual searching.”
Pipelinepharma positions itself as part of a larger modernization effort within pharmaceutical commerce. The company continues expanding its CTD dossier database while supporting sourcing, licensing, M&A discussions, and manufacturing partnerships across multiple markets.
For Zagorskis, the long-term opportunity extends beyond building a database. He believes the pharmaceutical industry is gradually moving toward a more connected global ecosystem where access to reliable information becomes a competitive advantage.
“The companies that adapt fastest to data-driven dealmaking will likely move faster in portfolio development and international growth,” Zagorskis says. “This industry is becoming more digital, more global, and more interconnected every year.”
